Cerebral Palsy Treatment Global Market Report 2024

The cerebral palsy treatment market size has grown steadily in recent years. It will grow from $3.33 billion in 2023 to $3.49 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth observed in the historic period in the field of cerebral palsy treatment can be attributed to several factors. These include advancements in medical techniques, the development of rehabilitation strategies, awareness campaigns fostering understanding of cerebral palsy, implementation of early intervention programs, and innovations in surgical approaches. These collective efforts have contributed to the progress and improvement in the treatment and management of cerebral palsy over time.

The cerebral palsy treatment market size is expected to see steady growth in the next few years. It will grow to $4.05 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The anticipated growth in the forecast period in the realm of cerebral palsy treatment can be attributed to the adoption of personalized treatment approaches, ongoing research in regenerative medicine, the expansion of telemedicine services, supportive healthcare policies, and a focus on family-centered care. Key trends in this period include targeted neuroplasticity interventions, increased accessibility to therapies and services, advancements in assistive technologies, comprehensive lifespan care planning, and the integration of interdisciplinary care teams. These trends collectively contribute to the continuous improvement and evolution of cerebral palsy treatment strategies.

The expanding incidence of cerebral palsy is anticipated to drive the advancement of the cerebral palsy (CP) treatment market in the coming years. Cerebral palsy, a cluster of neurological conditions emerging in infancy or early childhood, permanently affects body movement and muscle control. The identification of new instances of cerebral palsy serves as a catalyst for the formulation of novel treatment methodologies and therapies. For example, in April 2022, data shared by Cerebral Palsy Guidance, a US-based organization offering resources and support to those impacted by cerebral palsy, revealed an annual birthrate of approximately 10,000 newborns diagnosed with the condition. Moreover, in the United States, an estimated 764,000 individuals, encompassing both children and adults, exhibit at least one sign of cerebral palsy. Thus, the rising prevalence of cerebral palsy fuels the growth trajectory of the cerebral palsy treatment market.

The cerebral palsy (CP) treatment market is expected to witness growth driven by the increasing prevalence of chronic diseases. Chronic diseases, lasting for more than a year and requiring ongoing medical attention, include conditions such as diabetes, cancer, arthritis, and others. Individuals affected by chronic diseases, especially certain neurological disorders or complications during pregnancy and childbirth, may face an elevated risk of giving birth to a child with cerebral palsy. For example, a McKinsey report anticipates a nearly 20% rise in the illness burden in the United States by 2040. Additionally, data from the Center for Disease Control and Prevention reveals that six in ten Americans live with at least one chronic disease. Hence, the growing prevalence of chronic diseases acts as a driving force for the cerebral palsy treatment market.

Rising technological integration emerges as a prominent trend gaining traction within the cerebral palsy treatment market. Major players in this sector are embracing innovative technologies to maintain their market standing. For instance, in May 2022, Myolyn, a US-based medical device company specializing in functional electrical stimulation and rehabilitation technology, secured approval from the US Food and Drug Administration (FDA) for the second version of its flagship product, MyoCycle. This innovative stationary exercise bike utilizes functional electrical stimulation (FES) technology, benefiting individuals with muscle weakness or paralysis, including those with spinal cord injury, stroke, Parkinson's disease, and cerebral palsy. The MyoCycle serves as a valuable tool for individuals encountering challenges in activating their muscles, contributing to improved health and muscle activation.

Strategic partnerships represent another prominent trend gaining momentum within the cerebral palsy treatment market. Major industry players are strategically aligning to fortify their positions in the market. For example, in November 2023, the Cerebral Palsy Alliance Research Foundation (CPARF), a US-based organization focused on transforming possibilities for people with cerebral palsy, expanded its collaboration with QBE North America (QBE), a Switzerland-based insurance company. This unique partnership aims to foster greater openness, accessibility, and inclusivity for individuals with cerebral palsy and co-occurring disabilities. The collaborative efforts between CPARF and QBE underscore their commitment to effecting positive change and inclusiveness for those affected by cerebral palsy.

In November 2021, Supernus Pharmaceuticals, Inc., a biopharmaceutical company based in the United States specializing in treatments for central nervous system disorders, successfully acquired Adamas Pharmaceuticals, Inc. The acquisition, conducted for an undisclosed amount, bolsters Supernus Pharmaceuticals' product portfolio by incorporating GOCOVRI (amantadine). GOCOVRI, an FDA-approved treatment, is designed to address neurological conditions including Parkinson's disease and cerebral palsy. Adamas Pharmaceuticals, Inc., the acquired company, is based in the United States and is dedicated to developing therapies for chronic neurological disorders, including Parkinson's disease and cerebral palsy.

Major companies operating in the cerebral palsy treatment market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Co Ltd., Stryker Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Astellas Pharma Inc., UCB SA, Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Ipsen S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals Private Limited, Mallinckrodt plc, Glenmark Pharmaceuticals Ltd., Lupin Limited, Merz Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd., Almirall S.A., Wockhardt Ltd., Bioness Inc., Motek Medical B.V., Myomo Inc., ReWalk Robotics Ltd.

North America was the largest region in the cerebral palsy treatment market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cerebral palsy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cerebral palsy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary modalities of cerebral palsy treatment include surgery, therapy, and medication. Surgical interventions become relevant when non-surgical approaches prove insufficient in addressing symptoms or functional limitations. These procedures focus on improving mobility, correcting deformities, reducing spasticity, and enhancing overall quality of life. Medications, such as anticholinergics, anticonvulsants, antidepressants, and others, are employed to treat various types of cerebral palsy, including spastic, dyskinetic, ataxic, and mixed forms. These treatment options are made available through diverse channels, including hospitals, retail stores, pharmacies, and online providers.

The cerebral palsy treatment research report is one of a series of new reports that provides cerebral palsy treatment market statistics, including the cerebral palsy treatment industry's global market size, regional shares, competitors with a cerebral palsy treatment market share, detailed cerebral palsy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral palsy treatment industry. This cerebral palsy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cerebral palsy treatment market consists of revenues earned by entities providing services such as screening, diagnosis, and intervention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral palsy treatment market also includes sales of assistive devices, communication aids, and orthopedic equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.